ࡱ> n.aƑ*E2PNG  IHDR_^r_sRGB pHYs.> IDATx^O5 #xf ـî!` @ VmNrnI77Pt 9Y>f,A4 v!W55=ӣQij}_ս_r/Go)A-:e﮶>ol]y}t+{Hj?|t~?֙ӿ=zTkmWfhex[zFOmZ/H+o "+E4ǾGg0'sšj^otD \ Vngf?n?|(.:>ܬ$NΫ":yhIkXfs:2UGs3ޫ⋔~[CgR2oVv%({6fq# ܲzHZ2 1[uQ@OہV^j &/ o?x`}U S7̐JGTIœqɚm |t|aʘ+K{2e &vO͓w^fXq3R}00ٸpxJ_F t-.vI)ɄOrK@)Pƽ՛_Zp8, NNIde]^D:X|5&fq-a@GO tFCU]b6+:o]y~t4ϘPkLS1ՖMК"Rs3OCtdԕ)E[vHFK7Dy dgQ!lKw; GҀx:Ί|FG2̣\Y$|=t&er[:.JBFvJ'֥25Qaʭ BZ=Lz*:ʥA}T,\VKyR)$tndeDվĦ^a$tXY N+Xe"V 1а!gWb A< dL[f\OYZr0*\S mzJ3e:%glU:I^Cc4g|]&u_:Щ(q4hL:Mk9%d>q$6&ʶ$*H»WR|H" F#qt,Zv>ݥP}գAΉ St4 hZA'hZj`8$ŋAVW nȸZT@GD $+%JZД.e)_}{&ЉB`H[X8XWI"h8߬pW׬5HSZ)<\ڑt9=_>5Rwt\B?ru9=~''}wܣ;܇ 󳟯؝ ͋Ýkgxv|o~ ORf'Ĭ[b>{,aD|GyQڜyGZP# m;f,?U I{iKڌ0R;/yYiŒ?(1+ZF܊ [7RVF &n"/M;un:CYL@ B:(3^HgKvB|ndze>ShM[ Ll Ҭ7>4S b FUIQ-=9b7;bUdgњFǙ˧|wBA=檦ugLT7K-Tp"mVZ0[*,.R6U&qPs)hr2YJ3Cߘ@AcHJϯޓUج|V SbUpp_}T$@ (?^rL!eiXp;A.3 ~v9F˨H/y: T?S.*mZڊD@ЏrEgݻk:|?XT[~$Os%_0pT(4ok%IV**sY=uxJ?yV*.̥b LP\-WK*WJRB8ֿFP CG:Q :# Ge~W~8ף!2 mwR?P-e؈<1` +EeQf2~+ n?M]LO~QGb\|NGKFp'0n_Me N??dől_hxf|;\0(<rqz?}`N?aqz#$o@)+hLW:io-|gڞĶJ 0}0QTrw|Wn~,SEzlwpf>U^p<@&x(5SGЌ9s(m=S6:G:x,\2˅2|YJ:=8$|7WanFG+NZwbͨpW[DHjeuv.0M5*j,ˌZk\{*Ƒ vjVU+Iyɛ"ӭ$L|"J\Ʉ CUkwtټwu+%^(sP-\-V +2LKqk2a= _%o`}daII;K,~YgIIYrGϙ001rg(TNr^3%,Ri)}`9]hr.~9&?R"8s=:>ڳ mS?$<[ω|JM|k cJ =7= fͲ`ͯadžf*4Ɤ7s._ZRX/WBqqѬyzPNvg7|z>a/Ax'd}pڴ_j U]._;K NDٚ0< !g6nz1J38"F-joQnUUO(c"OO0|'ɽw%D+)Uj| ӛK PA~`+ɸ>>p>nϦLibx5:Jw'IO=.eJ{'d|{4E+G^RnuI3@"!޸]"&iEAC饓r{$5m{6v%KekvOgwSNDau%qW!2qñCiE5yy`VIj:sd;Ol3_$ۿ=`!._D=/6ūe MJ (Vkxڽ[}l[urDIJiUW}Rբq%5v*ۂmukAItͅ"7 4y]S @MDi2ENn 4E[tX0`-a ݹ{/?ޓXEw={sϽWAmi|ΐ2;k.:jX.ޮRq ԮڞjoREUݼ_dh'#λt}^TSN58Ϣ[lپg(g wcEB8Z* MRBmW3W,ٗodKl+Li-W)n3%{-TpɭR./_4:bF&&9Ns >Iԇɛ|A( 6|Hy7"uɻӅ(u n*6F]7khi3T:~nU&1n 0*֎#3T'CtG6CuCG;$DŽR~ڈJӨša6Hl'A08I|?<(u ko6mزL%!dF`cSsy>~F19y +RdL'zftUZ2~L_Agn俈V;Qw/SPw2@U̗ܝLr/`{`cLCA'{Ѳ~B//0|O=rQ슷sLecRqs[v?Jq8NګAiE]PGmnv+G,mR>olT`*35~bcdqp_"80Y:a,,@1UJ[׉Qc` p8>>Q"zGQ4Ov M])T%F6ĈS`Ok~H"G %eG0C7('ݲϬfWf!-mQaҳ0DB4 c2\o;ҽ\9kcR/ 1qN]e("0IFO:6l?!u\ ߏ ^V6!JO&}R}hjmR}b2Zģ?/*rk?9LW';J^KCE~ݒq *CWǃksGu|Cm$O Ϡr }!nI+gP9^qXZisn}Az/ v`KZѭm3h߷~>PSY(A=.zpr{r@e.9T)EIqk{'SFgQ7ǘu!ЊN2U[}釨u:CaǑDcWgZfPy!t 4]Љd}LKNk*W2%-.jR׎i ]JGyΟuj鼮8N$Q&ւ=_Ӵs>Qs^ɖ={:Ilwz :xGb{^<2NQ1e&:%"J9gDiZhֳ;kōډŁ:";~9LN."-ĴEZQr?X~HtVTeymzG3EqHyyaHe`\LE,-aa4?#4ŗEuEzjcUUS%i行ݺ|%=ENL7n<2"K;|nGZCvzx^ح/XvjL>_ .x`LI5x6S:mA =@MsԅX~qkoa4b&f$@^CI9KYwSgߍ%7SiZI?7b_Zrrk3ӅȪ$N2C,|B; f` =3Zk =3ZP _4/%`'Y#epQ-kW|Ӳ&"m,=>-"mYGڲi˚iz%MG hY;k<&l»[5z%A#PԖ:HȜZ3d| N)ᪧ&2A]Ut=]V%ZDسv5c-j+T]Kph{7H[m+{-Տn+hAmt b+X&J+FWr\I(̇SsƆ?|f T,;; ZYߒNLdV$z#K2Kd,Yz%K2q֨i'}\y81dj-ì.Zk IrBvNZ:~w/ 'L>*;G8mNB!lryp`o#>SM8PXCWc@×>0%Ǯޚߦ@t0yCܥ%TNvGFѮUGQFљ S(D$!->3>u!!X2+cE㮌 Sd\ty7g [a~% n&L|*B;93buo2/o(wq2,9|ql.f)[ɭUi 5L ;I5D{]-io͠xu4I/^N! |&^.i^.4yFsBe'".ƣOi}u7F_GA7) 7RƏġ-!!eo H gzݝ vZ5>>[|kFr7^3N|\Ög5TANK_3~PGǒ,ssgZ.b¿V{(4nhAt bd,:>ko_YϤʃD[Ao`ӜnE-0UxD%&j FFGGlgf74ER:M):3cI>"4?d?Ƒ4YӌF\I\뀚$]$ \њ"j|O{Kf]a%?֩]= ݛD߇VNM) +acbjaԿM@⽢+n^yrXwGhUs׷WMɷOjطWM^5۫MZmPkYĎ-IǤ&=N46l9Y8i-4j=6#_gxX|7[9_:Fmܴ_~)Ř+m=2Lx2eS8"D=f:-H[-NG=-R"С,LY1>:RV\iLڛmߵm;mm3mwmێܶXm[ˉT ?E#^Xkv,^͌LjFXbl٩XͼC#=ɤݨ ^2)+n"4O31%D5OihHHsח0&Oxe Gr-ƾ{3ZO|=O{ɦ|Kޝg>% }m B5хb!g HuvqC>$jz'd{WO[h|rT|![/Ki %zde퐜/e!>&ِOl~X:۠g@9'90[S!Zm,_ QF$O݁.;q1W}vX{VϊaJjԶ[N|ū&t4kޅѷ/*gP9LWaGצs[OmsnyB-W0Ϡr]%9`Axŕq̪0em&ttyB [+"͢f (   wBitmap Image Paint.Picture0Bitmap Image 0Document Word.Document.80$Microsoft Document 0Document Word.Document.80$Microsoft DocumentTable 4 Major Hypertension Cardiovascular Prevention Trials.docb/ 0DTimes New RomanH0Wo 0 DSymbolew RomanH0Wo 0  ` .  @n?" dd@  @@`` X  7    22#?b$aƑ*E262$Ϲh"bw 62$_D=/6ūe6c $@_uʚ;2Nʚ;g4CdCd0.ppp@ <4!d!d 0L4<4dddd 0L4<4BdBd 0L4? %lGeriovascular Evidence6ZHow Applicable are the Major Cardiovascular Clinical Trials to the Geriatric Population[[$Basis for Therapy  Dyslipidemia Trials     Hypertension Trials 1 Hypertension Trials 2  +Major Clinical Trials ACE inhibitors in CHF Other Major Trials/  ` ` ̙33` 333MMM` ff3333f` f` f` 3>?" dd@,|?" dd@   " @ ` n?" dd@   @@``PR    @ ` ` p>> 0 x(     Nw ))?"0  w T Click to edit Master title style! !$  0pw " w RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  0Hw "`` w >   0w "`  w > Continuing Medical Implementation & ...bridging the care gap Vg&"&*  0dw "`  w D*  T32 @1?"`  T  @1?"x   <A ??"`X B  s *޽h ? ̙33 ,CMI copyright template 0 zP(    0 w P   w R*    0w    w T*  d  c $ ?  w  0w  @ w RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  6w `P  w R*    6$w `  w T*  H  0޽h ? ̙33  $(  r  S а   i r  S si P`   i H  0޽h ? ̙33   J B p (  ~  s */w 0   w  p 00  #""PP  <d3w? 0 h"Clinical judgment and common sense## @`  <,w? 0 X> 85 @`  <?w?0   `Evidence and extrapolation @`  <Lw?0   K75-85 @`  <Tw?0  NEvidence   @`   <Mw?0  K65-75 @`   6 |m?0 YTherapeutic basis @`   6(m?0 KAGE @``B   01 ?00ZB   s *1 ?ZB  s *1 ?0 0 ZB  s *1 ?  `B  01 ?00`B  01 ?00ZB  s *1 ?00`B  01 ?00H  0޽h ? ̙33c1  1 166$0(  $~ $ s *m 0   m / ` $ #"6* 0 $ C xxmxaxaԔ))?t  N71" @` $ C xmxaxaԔ))? t O4.8" @`. $ C xmxaxaԔ))?\  ~55, mean 664  " @` $ C xܫmxaxaԔ))? \ NALLHAT @` $ C xmxaxaԔ))?t   N85" @`  $ C xmxaxaԔ))? t  O3.2" @`   $ C x$mxaxaԔ))?\  \70-82 $" @`  $ C xmxaxaԔ))? \  OPROSPER @`  $ C xmxaxaԔ))?t   N85" @`  $ C xmxaxaԔ))?  t  M5" @` $ C xmxaxaԔ))?\  m40-80 (1263 pts 75-80) $" @` $ C xPmxaxaԔ))? \  KHPS @` $ C xmxaxaԔ))?t   N81" @` $ C x8mxaxaԔ))?  t  M6" @`  $ C xmxaxaԔ))?\   \31-75 $" @` $ C xmxaxaԔ))? \  MLIPID @` $ C x`1mxaxaԔ))?t%   N80" @` $ C x9mxaxaԔ))? % t  M5" @`  $ C xAmxaxaԔ))?\%   \21-75 $" @` $ C xDmxaxaԔ))?% \  LCARE @` $ C xlPmxaxaԔ))?t.%  N75" @` $ C xhXmxaxaԔ))? .t%  O5.4" @`  $ C x@`mxaxaԔ))?\. %  \35-70 $" @` $ C xxcmxaxaԔ))?.\%  J4S @` $ C xqmxaxaԔ))?tk. N78" @` $ C xixaxaԔ))? kt. O5.2" @` $ C x6ixaxaԔ))?\k . f45-73 M 55-73 W $" @`$ $ C x9ixaxaԔ))?k\. t AF/TexCAPS   @`  $ C xH0ixaxaԔ))?ttk N70" @` !$ C xMixaxaԔ))? ttk O4.9" @` "$ C xVixaxaԔ))?\t k S45-65 M" @` #$ C xkixaxaԔ))?t\k RWOSCOP" @` $$ 3 rP^ixaxaԔ))?t`t UMax Age" @` %$ 3 rvixaxaԔ))? `tt UF/U Age" @` &$ 3 r ixaxaԔ))?\` t [ Enrolment Age" @` '$ 3 r:ixaxaԔ))?`\t QTrial" @`B ($ 3 rxaxa1 ))?``B )$ # lxaxa1 ))?ttB *$ # lxaxa1 ))?kkB +$ # lxaxa1 ))?..B ,$ # lxaxa1 ))?% % B -$ # lxaxa1 ))?  B .$ # lxaxa1 ))?  B /$ # lxaxa1 ))?  B 0$ 3 rxaxa1 ))?B 1$ 3 rxaxa1 ))?`B 2$ # lxaxa1 ))?\`\B 3$ # lxaxa1 ))? ` B 4$ # lxaxa1 ))?t`tB 5$ 3 rxaxa1 ))?`B 6$ # lxaxa1 ))?  H $ 0޽h ?   ,$(  ,~ , s *i 0   m f , s *A ??x B , s *޽h ? ,  ,z,114,(  4~ 4 s *Li 0   i T+ 0 4 #"2& rrsrrrsr0 4 3 rixaxaԔ))?h0 UMax Age" @` 4 3 rixaxaԔ))? h UF/U Age" @` 4 3 rixaxaԔ))?  [ Enrolment Age" @` 4 3 rixaxaԔ))? QTrial" @` 4 C xixaxaԔ))?h.0 P88.5" @`  4 C xixaxaԔ))? .h O4.5" @`  4 C x$ixaxaԔ))?.  Q70-84" @`  4 C xwxaxaԔ))?. W STOP-2 (48)  " @`  4 C xwxaxaԔ))?h 0. P72.1" @`  4 C x\wxaxaԔ))? h. O6.1" @` 4 C xwxaxaԔ))? . X 52.6 (25-66)  " @` 4 C xwxaxaԔ))? . V CAPPP (47)  " @` 4 C xwxaxaԔ))?hI 0  P83.7" @` 4 C xmxaxaԔ))? I h  O3.7" @` 4 C x mxaxaԔ))?I  X 61.5 (50-80)  " @` 4 C xixaxaԔ))?I   THOT (46)  " @` 4 C xixaxaԔ))?h 0I  P72.2" @`  4 C x xaxaԔ))? hI  ZMedian 2 years" @` 4 C xxaxaԔ))? I  `> 60 (mean age 70.2)" @`5 4 C x xaxaԔ))? I   Syst-Eur (45)"$ @` 4 C xxaxaԔ))?h0  N89" @`  4 C xxaxaԔ))? h  \Mean 25(6-65) mo" @` 4 C xX'xaxaԔ))?  Q70-84" @` 4 C x0/xaxaԔ))?  X STOP-H (444)  " @` 4 C x7xaxaԔ))?hf0 N77" @` 4 C xl?xaxaԔ))? fh S5 years" @`  4 C xhxaxaԔ))?f  Z> 65 (mean 72)" @` 4 C xJxaxaԔ))?f U SHEP (43)  " @`  4 C x,XxaxaԔ))?h0f P76.7" @` !4 C x_xaxaԔ))? hf O4.7" @`( "4 C xRxaxaԔ))? f x 60 (mean 72)*" @` #4 C xjxaxaԔ))?f V EWPHE (42)  " @`B $4 3 rxaxa1 ))?0B %4 # lxaxa1 ))?f0fB &4 # lxaxa1 ))?0B '4 # lxaxa1 ))? 0 B (4 # lxaxa1 ))?I 0I B )4 # lxaxa1 ))? 0 B *4 # lxaxa1 ))?.0.B +4 3 rxaxa1 ))?0B ,4 3 rxaxa1 ))?B -4 # lxaxa1 ))?B .4 # lxaxa1 ))?  B /4 # lxaxa1 ))?hhB 04 3 rxaxa1 ))?00B 14 # lxaxa1 ))?0H 4 0޽h ? ,  V,N,11<+(  <~ < s * 0    (+ 0 < #"2& rrsrrrsr0% < 3 r,xaxaԔ))?h0 UMax Age" @` < 3 r܇xaxaԔ))? h UF/U Age" @` < 3 r,xaxaԔ))?  [ Enrolment Age" @` < 3 rНxaxaԔ))? QTrial" @` < C xxaxaԔ))?h-0 W Mean age 67  " @`  < C xPxaxaԔ))? -h ^4.9 year follow-up" @`  < C xTxaxaԔ))?-  X 33,357 55-64  " @`  < C xxaxaԔ))?- W ALLHAT (57)  " @`  < C xƆxaxaԔ))?h 0- _"  @`  < C xΆxaxaԔ))? h- W In progress  " @` < C xՆxaxaԔ))? - P> 80" @` < C x݆xaxaԔ))? - V HYVET (56)  " @` < C x,xaxaԔ))?hH 0  O85+" @` < C xxaxaԔ))? H h  S5 years" @`  < C xxaxaԔ))?H  Z70-89 (21%>80)" @`  < C x$xaxaԔ))?H   Y SCOPE (54,55)" @` < C xTxaxaԔ))?h 0H  P84.8" @` < C x xaxaԔ))? hH  O4.8" @` < C x8xaxaԔ))? H  Q55-80" @` < C xxaxaԔ))? H  U LIFE (53)  " @` < C x\'xaxaԔ))?h 0  P69.9" @` < C xd)xaxaԔ))?  h  O3.9" @` < C x0xaxaԔ))?  V Mean 63-65  " @`  < C x9xaxaԔ))?   \PROGRESS (51,52)" @` < C x4GxaxaԔ))?hf0  N85" @` < C x 60)" @` < C x ZxaxaԔ))?f  X INSIGHT (50)  " @`  < C x`xaxaԔ))?h0f P84.5" @` !< C x$jxaxaԔ))? hf O4.5" @` "< C xpxaxaԔ))? f X 60.5 (55-80)  " @` #< C x~xaxaԔ))?f W NORDIL (49)  " @`B $< 3 rxaxa1 ))?0B %< # lxaxa1 ))?f0fB &< # lxaxa1 ))? 0 B '< # lxaxa1 ))? 0 B (< # lxaxa1 ))?H 0H B )< # lxaxa1 ))? 0 B *< # lxaxa1 ))?-0-B +< 3 rxaxa1 ))?0B ,< 3 rxaxa1 ))?B -< # lxaxa1 ))?B .< # lxaxa1 ))?  B /< # lxaxa1 ))?hhB 0< 3 rxaxa1 ))?00B 1< # lxaxa1 ))?0H < 0޽h ? $  Dd(  D~ D s *0~ 0     D s *A ??S,L  0 0H D 0޽h ? J  0""L(  L~ L s * 0    t }p L #"&DDDDD}p L 6?} QMax age @` L 6?@ } YFollow-up years @` L 6?x}@  XEnrollment Age @` L 6?}x OTrial @` L <?, p L70 @`  L <?@ , p M4.8 @`  L <$·?x, @ p Q65 mean @`  L <Ї?, xp MAtlas @`  L <,އ? ,  N80.7 @`  L <?@ ,  M5.7 @` L <4?x @ ,  O18-75 @` L <? x,  s V-HeFT II   @` L <?   N85.2 @` L <?@   M5.2 @` L <l ?x @  O21-80 @` L <l? x  YSOLVD prevention @` L < ?  N84.6 @` L <(?@   M4.6 @` L <0?x@  O21-80 @` L <08?x  XSOLVD treatment @``B L 01 ?}}ZB L s *1 ?  ZB L s *1 ?  ZB L s *1 ?, , `B L 01 ?pp`B L 01 ?}pZB L s *1 ?x}xpZB L s *1 ?@ }@ pZB  L s *1 ?}p`B !L 01 ?}pZB "L s *1 ?H L 0޽h ? ̙33   PTL(  T~ T s *H 0    p  T #"" E T 6\L? SMax age @` T 6O?@  [Follow-up years @` T 6W?x@  ZEnrollment Age @` T 6_?x OTrial @` T <,h?  \66 7$" @`  T <|p?@   n$3.75 Terminated early due to benefit%% @`  T <~?x @  `55 5128/9127= 55% > 65 @`  T < ? x LHOPE @`  T <?   L80 @`  T < ?@   L3  @` T <<?x @   g65 12." @` T <@? x  MRALES @` T <?  f425 80$  @` T <ܱ?@   N3.1  @` T <?x@  dMean age 63.4 (2417 > 70) @` T <?x  Q DIG Trial   @``B T 01 ?ZB T s *1 ?  ZB T s *1 ?  `B T 01 ?`B T 01 ?ZB T s *1 ?xxZB T s *1 ?@ @ ZB T s *1 ?`B T 01 ?ZB T s *1 ?H T 0޽h ? ̙33 0  ((   ^  S    m  c $ m @  m  H  0޽h ? ̙33 0 (((  (^ (S    i (c $̮i @  i  H ( 0޽h ? ̙33 0 0((  0^ 0S    i 0c $di @  i  H 0 0޽h ? ̙33 0 8((  8^ 8S     8c ${ @    H 8 0޽h ? ̙33 0 @((  @^ @S     @c $t @    H @ 0޽h ? ̙33 0  H((  H^ HS     Hc $ @    H H 0޽h ? ̙33 0 @P((  P^ PS     Pc $C @    H P 0޽h ? ̙33  0 `X((  X^ XS     Xc $щ @    H X 0޽h ? ̙33 xF9 BB0~#$@'&_1b/t "S%5'흮vFJo{jzK+iG3yH[yە?3>ɮU7e7íY~pH>Z_Cr#M$GILZ[H^*Fr;I yɝ$o$9N&$w-$w$$yɻIC^$$ɇI>Br^|$ $<e mvYy/kC)`7oOX^}(Y e.9/LCl]WPȁJ:-!2*ca;hOj>)鋆DF'2tcB"E6J=Jl8:S9^WrG|0cVdmMxuhI9I-^>bKm)BӦyVFŔB%4icKH&7_MڢtF]Qu^Ks)miҷuŒPQqC]@ Y/jÙTiڼ)>hH2=3bn j-a**-]o[m巺ib6}Th4:R(%>/lpvFiűSP+A-눿&_iDlM&Xx4em`C˱.LJT CBH<ʹlJ#i jO{Ϋ ^-e ˃G!T91)bٶ /'9J3$bZ##=8HF3TQmʚ Zz[>l|04etz쿊-M_hҾ|ɭ4:IKͷQͭH[&"}fX6p4Rke&> GkqB!ibU eOڨlhˋsPB$h}|А 9e"ADcy0rhR5el%)ѵpтh- I ֺI>6H@ZDakrk:|ZWKv9F lіFL">>~kz(%0i)|x&2 q')ק6S.ߧLCddGF EXJ-L ʬ-tI&zi> `(>oNO>9Our櫀0>C\!|UҾ&ŇA*'<ᔧ'ݽ}IasLOG |~_L |66BOԻ*<}dz#\V>3xgf,>y0DT|Ē<{ߣA/7Ƨtj|NG>Kml>|QD]>yPՌV>:Q ّO:&>yw8D5MsO ϔGtc/iGϗU)jSw3؃'ݹӡ >6&C>55 >99R|&չ'_^M!N!a)rb^3lvK-/H\e>(@(_yQɶd|O}sd[|ht>g8#.v+? +aNyR{NyhL_%F!G ħuC蹇= sI>ѵ yf bDS67?`Ƭ~ۚX_ђ~|R 5mA c;JEiC{h"ˆuTt=%bZŅ-ʧrm>B>2lƊҕ6,H 4{h3{I qmB{h +"iY [P@Tpm6hPJ2atS=6C["6V{j/EO{hl"){hk⓻6>R^|C[=6s{hK=ř{hk;=ұtmmNGAC[b=rmX8smm=&qbڒtmmk5=%=EЖ{hk3֖{hK=ұe-{hK=Ez Ж3Ж)hY>E[윏=]WBX~E=<xelLBNx\{ly}QRx$CXy$O4U6KҲbJb$9QiYi0Zֵۈcdž9AF FPlK汻;풧S{<j~ӱ7)kQPHSxfTk׬k>TxV@F |B%* B-:@Ch6!4Bh!4Chp Vm\y(Ya8ȮOcɢAc/K(˧DdIlBBt_Db4_G2Q" AO?uOM޵%Z3wdL,y&xx7{|:5OOCCx059gT'l:=2:1pc?p.ΘLzҘNp*;StdʜˤةAEMk1 E6Ǐ{GFÇ@ 'PAf =@sh& g BZQ4Ðs8MZ˄&B,d@?'4-}Cc?a@>!aSk΀ 0 妩~L%OR)(9I%&>CSqAVdt'%-~T%a ^uu?}Q*~r'~?xK5_οZ_݀vo(Nsn:> 㠣I7:Q;5;C\wwB;Fni,_DƷ-BBLu~s<3lUu+<1z?'h`| MMe#N?0]#ĥ7j{bko8=@$8t7Qа OpRHR 8  }^f-WO w?/v-R/}YH 1ܯRyg>'B}Ƀ&"H\;հ'utp.?Y'9375o2<"ɷJhcc者*i-cgYcڄvԡ}{HR &IՎ 0Ndn:E-]<+6PI/*iU&~ }^q4N] H`CB# q @~fD:Z36{Rߤ|C)WZh['j-F4&&i&1 7bFWzD_$S{U~0. }Nq]n6w`>@ *w.Y9@y&Y%[ hxӶ{Kԝn^1+%V9 }7ިJm7\g*?~g||+n'dfӄehQj`+K=`o~{kO-{snj6BpU\x4A2+xZ.{hD)(-oxW[n t1u34`zn Cj>a@A+@~UjF'JjnZqۭ*?75Rdss3f'd0M>Ea 6oo(mimw+a3 IQ{Jqm'FJ l6(Do+Ď5(3UCniz24V6>A=̱@+AJG)oq=@%= ðڗ5|uZGfحض o&R9oQ;@`IdRƱf u!ڲ0uc< +!Ry2RrkFG\>dOM3Dz*mLR.٘x:5**[UXKV>#gAomKR|e\n1x,(wO+ /;֚i=:I۝5N٫i%"2kam3x錩Ni%FdvX \o{<t츨~혷(~uWX:𢡄Ӗq5iyP^vL炲~tmx;׷-(1ߧlmJ $iRkwrPӘ_$rڳPկI"k*򝊐B{UеWuct}{]7{>=UB]R_v-玐|;ZY(aGcـ{rcXQfv ޲șfŚ.0k1~g-RyY/ Ew|N8׎ dQŖ+0/cj5v ~KMf*<Sʆ(˭ny_;u ȁ!׮ n(rnY1^淁MGIs;\]P^ {vﳔ gl])gL_]qv^QH>86xpNzB jhnZ:V~#\QNP[ݝODx^VG\EXWTUȉEn IM#)Mrz\/j."[m]rzE㪅Em@ȇ|dʜMͦ O3:T VSnhWG,f }7K,ɨg %WldT,ɨn sq;B5Q#2(=f3_v:f͗wk-kvwIɨެɨߐ~2mfeT7v B%'n%KwIneBjGr6-X-vaUgY 9K8Q;ݧ q_RwD8iqfe Y8Kxq>9[HǍ_Q+{%KEW![l+J[HĖ^G4[$DlY2BAFG䋨_V-0vu^͔)oLh~扈&aJnZhŗ&%w%y%KD%{"ZUD+>D4%v27jѤu$J/T UtE2)idK7 7oS{;7{?)a+.,'9YB)|`ˏ8:ͽrдzd<Z+_ȑ0_ma4I+^פ9w5S7)I)|~7S6SKILILYŔ [Va_Q:e % 0+ѳE'eO,= xE G\6WH>Grq/^2g 0Y^%/jc/gE_/IMNm UjҩUiIKwtIsɒd(G$do,Ȓđx(YH(9o롳V`[v^#f63,3C7;0KٱdO_?;NXѧ7YȽҿB!'MNdO27%nЯǍzAxΞDZ9hCbAk-s󭯫[`Q{>ˠSwCBr-n͌˚ U܆W'N[mqqN޸ڌwrLϦ,LOMy#;Awg`غ@ 96Ç?iw&87;*{]w Iϙs H ~C`DfnҘı0߳o7!&TI3)SCtVDEDSԅԪs`U`ݸ 1pn ӷȻ8v>uj~;{z^YSZTiBN&wȧ19Nz$ȏ68J@dhqNMC_e0}nқ?xwOϹNV1ZOxү>K@ӥ7sT`1 zxLĮw5hܧEZLڄTƾmc/T y Qs5q<ݴ>u:8\/^x9mb7Wןa{cT.,3ȉ1bfl~!oL$ɉ\L*[HٓǓә1`G2sơs\hIfd~f!V+8p̚3`׿_nW=:(wȓ#S{OG'=1:wxtlt|(+` ڇN# nQ`W;u^Q4PsOUPfNxPsqM8PLd(hD|?ƗҒpw>D k)YT PϩaجJnO5/w+ߖkS6C_ _֠'zI]mi@|z Fߋ~~jEvI|ߢ [N/D|K\k0/!Py~ϕ0~QS{ލg|g&_/O}y Ǝ=qsFœYxO~'ҟ࠴銝^#[$/=#H0'~xد*0Bgu x.tIR'Sl7suHz&gSƓaժ}~6,ZEUw;/M xV뿇Ѝqk[T/տ`y}5Oϥx1i%+[P[sAG9)&R?qfc f;dGV=vD 7v1Ҧ 6 h7 PI.5Ƈs'=>.ЎbՍ A$pA%N5F[eW8,̃Fl!ƨxHFMoCw 4?\tHKSJ3&[k C-ΡU5$^`- 9thhhlFWlZ:zFy3sao*5%eBCȈm ,0˵U0vR{| fS( 0tc5x?{%OſZFP[ǟ[ȸ=r3`O,|Y\27|Fǐv!o_Um7Է^foۅ^fg4<K% 8=5̅ E_c1*LP+A!!⛫7FeOzۨj=$]dvBA~ڡX0C/ܗ 9B9@F Jfu@ 2Ш$5Ej@muqxBoc5ۭeZh{ *F!:-r,# kQ柶C2GҀj~b{e-$u&og3iXfRm3D9@z&v`6L׃6ޛ+M$,NΦ)#`|^TƪИ8cJ^#hOͤOSFl`NxfIft߰}d˽_A_Vw;Edl/":Y}h޻=c:kIģ<(/ k'=<ۈLw+te^VVGD_A[z;|2">ѵw\I\p\f֜OvP#Ed\!M #WH3U;Ew' iL4S#͒i 0T# ء k?je;|TˆfkDĆ!/^MuZZ^Sսv&/n푱&_v2vD+a\ӂ͎Θd&=kd;H;ǙV3`=l&s x w33ff'ն\iQ3hy N)T*-j0%5tV5~G&Gnmd]D̊Y?lC̊ ĬE̊ 1}"gblwg9mnx-6 [em*̊ 3纍si@Nz`F9#$Y[ YDh'_g>Yffaf5fVTטY)bf3§<({^gO[Γ_М\ܡrtoZc(*E:FIewh2.kGDc2l_}38nڵkZeĴ47Abw$aCJ-CJ;y^GӠ*p;o.Mkߒt0M% N!]jdY&uE۪ym{ġ k킕^ѾUǮwm<:Rhw Vma b^߸_2Le Q2z z@1p,Nf{ X: ED {Änq̀rpn۵Ru[SW̻zbFP?Z6P[ 9KIesNgX;pG[;ɲAb#Om"OEȿaW:Y.֒@|g MZ}9ǝw^|u}ےo㾍t}ےϽo[ɾmc0~/|+Ɏd{_-d5;/%n\.+tۗKJQfӨ~Q3۞si313YJCzV|YO6Y;뜈R?&],21%̨HoYL=~H#G'0X,=1w2/O9Qf8n׊{Կf|Ϭߣ0y(:P1'tP1Fw)p5n"sAB3=WF~C5z[D}t"_șO`%S4o6߾M1D"}CHU9R< ik{fQA͓o J{Ok)Cӵ>S]>JiWr2c)k t XgYN^ SR/ls]N21%プ([=7;NoY2zj ϺJyrQs|LZӭ/9޾;go5 >랿*=^V0Oz<_ԣ|Ϋ0e2x)Lu_F^b?-.S_r`pf2| mY*f\L^&ԷRfF&%nOh+'00R hp ( H T `ltGeriovascular Evidence J Niznickla\C:\Program Files\Microsoft Office\Templates\Presentation Designs\CMI copyright template.pot J Niznick F1NiMicrosoft PowerPointoso@0))@ @>3]GPg  R('& &&#TNPP2OMi & TNPP &&TNPP     'A x(xKʦ """)))UUUMMMBBB999|PP3f3333f333ff3fffff3f3f̙f3333f3333333333f3333333f3f33ff3f3f3f3333f3333333f3̙33333f333ff3ffffff3f33f3ff3f3f3ffff3fffffffff3fffffff3f̙ffff3ff333f3ff33fff33f3ff̙3f3f3333f333ff3fffff̙̙3̙f̙̙̙3f̙3f3f3333f333ff3fffff3f3f̙3ffffffffff!___wwwBBBBBBBBkBBBkBkBkBkBkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkBkBkBkBBBkBBBBBBBBBBBBBBBBBBBBBBBkBBBkBkBkBkkkkkkkkkkkkkBkBkBkBkBBBBBBBBBBBBBBBppp␐»⑹»⺼⻺޻ݝpqqq⑁qpp⼻pppqqq»pppppp⑺qp񻻻pqpqpq--&TNPP &՜.+,D՜.+,$    EOn-screen Shown-sJT  Times New RomanSymbolCMI copyright templatesCCS Geriatric CVD Consensus Panel\Prevention\Table 5 Major Dyslipidemia and Cardiovascular Prevention Trials.docnCCS Geriatric CVD Consensus Panel\Prevention\Table 4 Major Hypertension Cardiovascular Prevention Trials.doc Bitmap ImageGeriovascular EvidenceBasis for TherapyDyslipidemia Trials PowerPoint PresentationHypertension Trials 1Hypertension Trials 2PowerPoint Presentation,Major Clinical Trials ACE inhibitors in CHFOther Major Trials   Fonts UsedDesign TemplateLinksEmbedded OLE Servers Slide Titles h 8@ _PID_HLINKSA t..\..\CCS Geriatric CVD Consensus Panel\Prevention\Table 4 Major Hypertension Cardiovascular Prevention Trials.doc!_& CJ NiznickJ Niznick  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root EntrydO)Pictures.Current UserSummaryInformation(`RPowerPoint Document(:&DocumentSummaryInformation8